Video

Dr. Kambhampati on Venetoclax in Patients With Myeloid Malignancies

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Cancer Institute, discusses the impact of single-agent venetoclax (Venclexta) in patients with myeloid malignancies.

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Cancer Institute, discusses the impact of single-agent venetoclax (Venclexta) in patients with myeloid malignancies.

What is unique about venetoclax is its ability to overcome a key rate-limiting molecular vent in myeloid malignancies. Though that is common in many malignancies, there is a particular lack of chemotherapy efficacy in myeloid malignancies due to the TP53 mutation. Venetoclax can work downstream of P53 and lead to the restoration of chemotherapy responsiveness; that's the “Holy grail,” of cancer therapy, he says.

It's shown success in patients with high-risk acute myeloid leukemia who traditionally were treated with non-intensive chemotherapy approaches. Previously, there wasn’t a big difference in a patients’ overall survival (OS), but now there’s a remarkable prolongation of their OS by venetoclax. The treatment is not trivial, and there are significant side effects that need to be monitored, but it’s a step forward in the field of myeloid malignancies, he concludes.

Related Videos
Sujith Samarasinghe, MD
Suzanne Trudel, MSc, MD
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Sundar Jagannath, MBBS
Kevin Kalinsky, MD, MS,
Aaron Gerds, MD
Paolo Tarantino, MD
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Shella Saint Fleur-Lominy, MD, PhD